
Incyte (INCY) Stock Forecast & Price Target
Incyte (INCY) Analyst Ratings
Bulls say
Incyte Corporation's positive outlook is strongly supported by robust revenue growth driven by increased demand for its leading drug, Jakafi, which experienced a 10% year-over-year increase in paid demand across all indications. The commercial performance of Opzelura, with revenue surpassing expectations at $188 million, underlines the firm’s ability to capitalize on the growing patient demand in dermatology for atopic dermatitis and vitiligo treatments. Furthermore, Incyte's raised fiscal year 2025 guidance to a range of $4.23 billion to $4.32 billion highlights confidence in its oncology portfolio, including Jakafi and other marketed products, indicating strong future financial prospects.
Bears say
Incyte faces significant downside risks primarily due to the erosion of pricing power for its leading drug, Jakafi, which is critical for its sales growth. The firm is also encountering challenges with the performance of its earlier-stage pipeline and potential clinical or regulatory setbacks associated with Jakafi’s combinations. Coupled with competition in the market and concerns regarding safety and efficacy of both marketed products and ongoing clinical trials, these factors contribute to a negative outlook for Incyte's stock.
This aggregate rating is based on analysts' research of Incyte and is not a guaranteed prediction by Public.com or investment advice.
Incyte (INCY) Analyst Forecast & Price Prediction
Start investing in Incyte (INCY)
Order type
Buy in
Order amount
Est. shares
0 shares